Cargando…

Long-term efficacy of vildagliptin in patients with type 2 diabetes undergoing hemodialysis

BACKGROUND: There are few studies evaluating long-term glycemic control using a dipeptidyl peptidase-4 inhibitor in type 2 diabetes patients with end-stage renal disease (ESRD). The aim of this study was to evaluate the safety and efficacy of vildagliptin therapy over 2 years in type 2 diabetes with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mera, Jun-ichiro, Okada, Eiko, Okuda, Masumi, Ota, Tatsuru, Sibata, Shigeru, Uchida, Shunya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635589/ https://www.ncbi.nlm.nih.gov/pubmed/26550558 http://dx.doi.org/10.1186/s40200-015-0214-6

Ejemplares similares

Hyperkalemia in patients undergoing hemodialysis: Its pathophysiology and management
por: Shibata, Shigeru, et al.
Publicado: (2021)

Efficacy and tolerability of vildagliptin in type 2 diabetic patients on hemodialysis
por: Kume, Shinji, et al.
Publicado: (2012)

Remission of Refractory Ascites and Discontinuation of Hemodialysis after Additional Rituximab to Long-term Glucocorticoid Therapy in a Patient with TAFRO Syndrome
por: Tsurumi, Hanako, et al.
Publicado: (2018)

Vildagliptin is Effective for Glycemic Control in Diabetic Patients Undergoing either Hemodialysis or Peritoneal Dialysis
por: Ito, Hiroyuki, et al.
Publicado: (2013)

Discontinuation of Hemodialysis in a Patient with Anti-GBM Disease by the Treatment with Corticosteroids and Plasmapheresis despite Several Predictors for Dialysis-Dependence
por: Fujigaki, Yoshihide, et al.
Publicado: (2017)

The Efficacy of Vildagliptin in Korean Patients with Type 2 Diabetes
por: Moon, Jun Sung, et al.
Publicado: (2013)

Data on vildagliptin and vildagliptin plus metformin combination in type-2 diabetes mellitus management
por: Das, Sambit, et al.
Publicado: (2021)

Efficacy and safety of nateglinide plus vildagliptin combination therapy compared with switching to vildagliptin in type 2 diabetes patients inadequately controlled with nateglinide
por: Kudo‐Fujimaki, Kyoko, et al.
Publicado: (2013)

Unique proximal tubular cell injury and the development of acute kidney injury in adult patients with minimal change nephrotic syndrome
por: Fujigaki, Yoshihide, et al.
Publicado: (2017)

Profile of vildagliptin in type 2 diabetes: efficacy, safety, and patient acceptability
por: Pan, CY, et al.
Publicado: (2013)

The Efficacy of Vildagliptin Concomitant With Insulin Therapy in Type 2 Diabetic Subjects
por: Ito, Daisuke, et al.
Publicado: (2015)

Ten Years of Vildagliptin
por: Del Prato, Stefano
Publicado: (2017)

Surfing the Vildagliptin Tsunami
por: Balachandran, Karthik
Publicado: (2020)

Efficacy and short-term side effects of sitagliptin, vildagliptin and saxagliptin in Chinese diabetes: a randomized clinical trial
por: Zhou, Xiao-jun, et al.
Publicado: (2019)

Fasting during Ramadan: efficacy, safety, and patient acceptability of vildagliptin in diabetic patients
por: Aziz, Kamran MA
Publicado: (2015)

Time-dependent risk factors associated with the decline of estimated GFR in CKD patients
por: Chang, Wen-xiu, et al.
Publicado: (2015)

Clinical Presentation of Tubulointerstitial Nephritis Caused by Amyloid Light-chain Amyloidosis in a Patient with Sjögren's Syndrome
por: Inoue, Reiko, et al.
Publicado: (2017)

Efficacy and Safety of Vildagliptin as an Add-On Therapy in Inadequately Controlled Type 2 Diabetes Patients Treated With Basal Insulin
por: Saito, Daisuke, et al.
Publicado: (2017)

Effect of Vildagliptin on Hepatic Steatosis
por: Macauley, Mavin, et al.
Publicado: (2015)

Glycated Albumin Predicts Long-term Survival in Patients Undergoing Hemodialysis
por: Lu, Chien-Lin, et al.
Publicado: (2016)

Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment
por: Lukashevich, Valentina, et al.
Publicado: (2013)

Efficacy and Safety of Vildagliptin as Add-on to Metformin in Japanese Patients with Type 2 Diabetes Mellitus
por: Odawara, Masato, et al.
Publicado: (2014)

Comparison of empagliflozin and vildagliptin for efficacy and safety in type 2 diabetes mellitus in the Pakistani population
por: Khan, Asima, et al.
Publicado: (2022)

Emergence of Smoldering ANCA-associated Glomerulonephritis during the Clinical Course of Mixed Connective Tissue Disease and Sjögren's Syndrome
por: Morimoto, Chikayuki, et al.
Publicado: (2017)

Range of motion of the ankle joint in male Japanese patients undergoing hemodialysis: influence of diabetes and hemodialysis
por: Matsui, Nobumasa, et al.
Publicado: (2019)

Effects of vildagliptin as add-on treatment in patients with type 2 diabetes mellitus: insights from long-term clinical studies in Japan
por: Odawara, Masato, et al.
Publicado: (2016)

Impact of timing of initiation of dialysis on long-term prognosis of patients undergoing hemodialysis
por: Zhang, Yumei, et al.
Publicado: (2018)

Impact of sarcopenia on long-term mortality and cardiovascular events in patients undergoing hemodialysis
por: Kim, Jwa-Kyung, et al.
Publicado: (2019)

Predictive Clinical Parameters and Glycemic Efficacy of Vildagliptin Treatment in Korean Subjects with Type 2 Diabetes
por: Chang, Jin-Sun, et al.
Publicado: (2013)

Efficacy and tolerability of vildagliptin as first line treatment in patients with diabetes type 2 in an outpatient setting
por: Yavropoulou, M. P., et al.
Publicado: (2015)

Mild acute pancreatitis with vildagliptin use
por: Saraogi, Ravikant, et al.
Publicado: (2012)

Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis
por: Wiciński, Michał, et al.
Publicado: (2020)

Predictors and the Subsequent Risk of End-Stage Renal Disease – Usefulness of 30% Decline in Estimated GFR over 2 Years
por: Chang, Wen Xiu, et al.
Publicado: (2015)

Effectiveness and Tolerability of Vildagliptin and the Single Pill Combination of Vildagliptin and Metformin in “Real-World” Management of Type 2 Diabetes Mellitus: The G-FORCE Study
por: Van Gaal, Luc, et al.
Publicado: (2019)

A Ruptured Jejunal Arterial Aneurysm in a Young Woman Undergoing Chronic Hemodialysis Due to Myeloperoxidase-antineutrophil Cytoplasmic Antibody-associated Vasculitis
por: Murakawa, Masataka, et al.
Publicado: (2021)

Vildagliptin Improves Endothelium-Dependent Vasodilatation in Type 2 Diabetes
por: van Poppel, Pleun C.M., et al.
Publicado: (2011)

Use of metformin and vildagliptin for treatment of type 2 diabetes in the elderly
por: Sicras-Mainar, Antoni, et al.
Publicado: (2014)

Vildagliptin increases butyrate-producing bacteria in the gut of diabetic rats
por: Zhang, Qian, et al.
Publicado: (2017)

Efficacy of Vildagliptin Added to Continuous Subcutaneous Insulin Infusion (CSII) in Hospitalized Patients with Type 2 Diabetes
por: Lyu, Fu-ping, et al.
Publicado: (2020)

Silver Nanoparticle Conjugation-Enhanced Antibacterial Efficacy of Clinically Approved Drugs Cephradine and Vildagliptin
por: Masri, Abdulkader, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_egsv8eode6b7nm9p6950gsp3op